Zhentao Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zhentao Liu has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Lin Shen
Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China
4 shared publications - Jing Gao
Department of Oncology Peking University Shenzhen Hospital Affiliated Hospital of Guangdong Medical University Cancer Institute of Shenzhen‐Peking University‐Hong Kong University of Science and Technology (PKU‐HKUST) Medical Center Shenzhen Guangdong China
3 shared publications - Jingyuan Wang
Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Fu-Cheng Road 52, Hai-Dian District, Beijing, 100142, China
3 shared publications - Zhongwu Li
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, China
3 shared publications - Zuhua Chen
Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Fu-Cheng Road 52, Hai-Dian District, Beijing, 100142, China
3 shared publications - Jianling Zou
Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Fu-Cheng Road 52, Hai-Dian District, Beijing, 100142, China
2 shared publications
Latest Publications
- Open Access
- 1 December 2024
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 15 (6) , 2496-2506
Regorafenib with or without chemotherapy/immunotherapy in second-line treatment of metastatic colorectal cancer during the COVID-19 pandemic: a single-center retrospective analysis
Background: Regorafenib, approved in China for the third-line treatment of patients with metastatic colorectal cancer (mCRC), targets multiple tyrosine kinases. We retrospectively evaluated the efficacy and safety of regorafenib, both as monotherapy and in combination with capecitabine or immune checkpoint inhibitors (ICIs), as a second-line treatment for patients unable to access hospital-based care due to limited hospital visits during the coronavirus disease 2019 (COVID-19) pandemic. Methods: Retrospective analysis was conducted on individual patient data from Peking University Third Hospital, covering the period from January 2020 to September 2023. The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall survival (OS) and safety. Results: The study comprised 31 patients with a median age of 65 years. The median PFS (mPFS) was 6.0 months, while the median OS (mOS) was 20.0 months. Compared to those treated with regorafenib alone, patients treated with regorafenib plus capecitabine/ICIs tended to have a longer PFS (8.0 vs. 4.0 months) and OS (27.0 vs. 15.0 months). Liver metastases [hazard ratio (HR) =2.515, 95% confidence interval (CI): 1.037–6.100; P=0.04] and prior bevacizumab treatment (HR =2.613, 95% CI: 1.168–5.846; P=0.02) were identified as independent prognostic factors for PFS. Frequent grade 3/4 adverse drug reactions (ADRs) included hand-foot skin reactions (HFSRs), fatigue, hypertension, and proteinuria. Conclusions: This single-center, retrospective study indicates that regorafenib, alone or combined with chemotherapy/immunotherapy, is a feasible and safe second-line treatment for mCRC for situations where hospital access is limited, such as during the COVID-19 pandemic. Additional prospective studies are required to investigate the advantages of combination therapies.
- 1 December 2024
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 15 (6) , 2496-2506
Open AccessRegorafenib with or without chemotherapy/immunotherapy in second-line treatment of metastatic colorectal cancer during the COVID-19 pandemic: a single-center retrospective analysis
Background: Regorafenib, approved in China for the third-line treatment of patients with metastatic colorectal cancer (mCRC), targets multiple tyrosine kinases. We retrospectively evaluated the efficacy and safety of regorafenib, both as monotherapy and in combination with capecitabine or immune checkpoint inhibitors (ICIs), as a second-line treatment for patients unable to access hospital-based care due to limited hospital visits during the coronavirus disease 2019 (COVID-19) pandemic. Methods: Retrospective analysis was conducted on individual patient data from Peking University Third Hospital, covering the period from January 2020 to September 2023. The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall survival (OS) and safety. Results: The study comprised 31 patients with a median age of 65 years. The median PFS (mPFS) was 6.0 months, while the median OS (mOS) was 20.0 months. Compared to those treated with regorafenib alone, patients treated with regorafenib plus capecitabine/ICIs tended to have a longer PFS (8.0 vs. 4.0 months) and OS (27.0 vs. 15.0 months). Liver metastases [hazard ratio (HR) =2.515, 95% confidence interval (CI): 1.037–6.100; P=0.04] and prior bevacizumab treatment (HR =2.613, 95% CI: 1.168–5.846; P=0.02) were identified as independent prognostic factors for PFS. Frequent grade 3/4 adverse drug reactions (ADRs) included hand-foot skin reactions (HFSRs), fatigue, hypertension, and proteinuria. Conclusions: This single-center, retrospective study indicates that regorafenib, alone or combined with chemotherapy/immunotherapy, is a feasible and safe second-line treatment for mCRC for situations where hospital access is limited, such as during the COVID-19 pandemic. Additional prospective studies are required to investigate the advantages of combination therapies.
- 30 April 2023
- Published by Asian Society for Sport Convergence Sciences in Asia Pacific Journal of Applied Sport Sciences
- Vol. 4 (1) , 31-47
Investigating Trends in Research on China’s Sport Policy Using Social Network Analysis and Topic Modeling
학술논문검색사이트 KISS는 학술논문,연구논문,연구자료,학술지 등 다양한 자료를 서비스하며, 주제별, 등재별, 인용지수, 인기논문, 이슈논문 등 다양한 키워드의 논문을 제공하여 빠른 학술검색 및 인용이 가능하도록 서비스합니다.
- 30 April 2023
- Published by Asian Society for Sport Convergence Sciences in Asia Pacific Journal of Applied Sport Sciences
- Vol. 4 (1) , 31-47
Investigating Trends in Research on China’s Sport Policy Using Social Network Analysis and Topic Modeling
학술논문검색사이트 KISS는 학술논문,연구논문,연구자료,학술지 등 다양한 자료를 서비스하며, 주제별, 등재별, 인용지수, 인기논문, 이슈논문 등 다양한 키워드의 논문을 제공하여 빠른 학술검색 및 인용이 가능하도록 서비스합니다.
- Open Access
- 17 January 2023
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 21 (1) , 1-12
Unmasking the biological function and regulatory mechanism of NOC2L: a novel inhibitor of histone acetyltransferase
NOC2 like nucleolar associated transcriptional repressor (NOC2L) was recently identified as a novel inhibitor of histone acetyltransferase (INHAT). NOC2L is found to have two INHAT function domains and regulates histone acetylation in a histone deacetylases (HDAC) independent manner, which is distinct from other INHATs. In this review, we summarize the biological function of NOC2L in histone acetylation regulation, P53-mediated transcription, ribosome RNA processing, certain development events and carcinogenesis. We propose that NOC2L may be explored as a potential biomarker and a therapeutic target in clinical practice.
- 17 January 2023
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 21 (1) , 1-12
Open AccessUnmasking the biological function and regulatory mechanism of NOC2L: a novel inhibitor of histone acetyltransferase
NOC2 like nucleolar associated transcriptional repressor (NOC2L) was recently identified as a novel inhibitor of histone acetyltransferase (INHAT). NOC2L is found to have two INHAT function domains and regulates histone acetylation in a histone deacetylases (HDAC) independent manner, which is distinct from other INHATs. In this review, we summarize the biological function of NOC2L in histone acetylation regulation, P53-mediated transcription, ribosome RNA processing, certain development events and carcinogenesis. We propose that NOC2L may be explored as a potential biomarker and a therapeutic target in clinical practice.
- 20 May 2022
- Published by ASME International in Journal of Engineering for Gas Turbines and Power
- Vol. 144 (6)
Investigation of the Effect of Simulated Atmospheric Conditions at Different Altitudes on the Combustion Process in a Heavy-Duty Diesel Engine Based on Zero-Dimensional Modeling
Plateau diesel engines suffer from increased fuel consumption and deteriorating emissions. These problems were mainly caused by the combustion worsening inside the chamber. However, limited research has been done specifically on the effect of altitude on the combustion process of diesel engine cycles, which would obviate the feasibility of optimizing high altitude engines. As a result, the goal of this study was to apply the zero-dimensional modeling approach to deeply analyze the influence of altitude on diesel engine combustion. A triple Wiebe function model was calibrated based on the experimental results of a turbocharged direct injection compression ignition engine operating at simulated atmospheric conditions from sea level to 5000 meters, where only the effect of pressure reduction was considered, but the intake temperature and oxygen to nitrogen ratio were kept constant. The analyses indicated that the increase in altitude lengthened the ignition delay, resulting in more fuel fraction being burned in the premixed combustion stage and therefore extending the duration of this phase. As for the main mixing-controlled combustion phase, operation at high altitude retarded the combustion initiation angle, advanced the combustion end angle, shortened the burning duration, and reduced the diesel mass burned in this stage. Moreover, the higher altitude operation increased the energy release and prolonged the duration of the late combustion period, which was detrimental to clean emissions. All these impacts contributed to the reduced thermal and combustion efficiency of the highland engines. However, the engine phasing did not change with increasing altitude, suggesting that it was mainly the combustion degradation that caused the reduction in power output. Consequently, finding solutions to improve the spray formation quality or the spray spatial distribution in lower density backgrounds is the key to compensate for the altitude negative effects.
- 20 May 2022
- Published by ASME International in Journal of Engineering for Gas Turbines and Power
- Vol. 144 (6)
Investigation of the Effect of Simulated Atmospheric Conditions at Different Altitudes on the Combustion Process in a Heavy-Duty Diesel Engine Based on Zero-Dimensional Modeling
Plateau diesel engines suffer from increased fuel consumption and deteriorating emissions. These problems were mainly caused by the combustion worsening inside the chamber. However, limited research has been done specifically on the effect of altitude on the combustion process of diesel engine cycles, which would obviate the feasibility of optimizing high altitude engines. As a result, the goal of this study was to apply the zero-dimensional modeling approach to deeply analyze the influence of altitude on diesel engine combustion. A triple Wiebe function model was calibrated based on the experimental results of a turbocharged direct injection compression ignition engine operating at simulated atmospheric conditions from sea level to 5000 meters, where only the effect of pressure reduction was considered, but the intake temperature and oxygen to nitrogen ratio were kept constant. The analyses indicated that the increase in altitude lengthened the ignition delay, resulting in more fuel fraction being burned in the premixed combustion stage and therefore extending the duration of this phase. As for the main mixing-controlled combustion phase, operation at high altitude retarded the combustion initiation angle, advanced the combustion end angle, shortened the burning duration, and reduced the diesel mass burned in this stage. Moreover, the higher altitude operation increased the energy release and prolonged the duration of the late combustion period, which was detrimental to clean emissions. All these impacts contributed to the reduced thermal and combustion efficiency of the highland engines. However, the engine phasing did not change with increasing altitude, suggesting that it was mainly the combustion degradation that caused the reduction in power output. Consequently, finding solutions to improve the spray formation quality or the spray spatial distribution in lower density backgrounds is the key to compensate for the altitude negative effects.
- Open Access
- 24 March 2021
- Published by EDP Sciences in E3S Web of Conferences
- Vol. 245, 03067
Establishment of plant regeneration system for young leaf explants of Cassia mimosoides
In the present study, a plant regeneration system was established by using young leaf explants from aseptic seedlings of Cassia mimosoides. The results showed that when the explants were inoculated on the 1/2MS medium contained 2.0 mg/L 6-BA and 0.5 mg/L NAA, high rate of callus induction and good growth status of adventitious bud, and the highest number of buds were obtained. Further studies conclusively suggested that IBA could not promote root formation effectively, but the root regeneration could be induced by NAA. However, although the rooting of regeneration buds could be induced when adventitious buds were placed into 1/2MS medium supplemented with 0.5 mg/L NAA, the rate of rooting was reduced, and the roots became shorter. Therefore, the best medium for adventitious bud regeneration using young leaf as explants in C. mimosoides was 1/2MS medium contained 2.0 mg/L 6-BA and 0.5 mg/L NAA, and the best rooting medium was 1/2MS.
- 24 March 2021
- Published by EDP Sciences in E3S Web of Conferences
- Vol. 245, 03067
Open AccessEstablishment of plant regeneration system for young leaf explants of Cassia mimosoides
In the present study, a plant regeneration system was established by using young leaf explants from aseptic seedlings of Cassia mimosoides. The results showed that when the explants were inoculated on the 1/2MS medium contained 2.0 mg/L 6-BA and 0.5 mg/L NAA, high rate of callus induction and good growth status of adventitious bud, and the highest number of buds were obtained. Further studies conclusively suggested that IBA could not promote root formation effectively, but the root regeneration could be induced by NAA. However, although the rooting of regeneration buds could be induced when adventitious buds were placed into 1/2MS medium supplemented with 0.5 mg/L NAA, the rate of rooting was reduced, and the roots became shorter. Therefore, the best medium for adventitious bud regeneration using young leaf as explants in C. mimosoides was 1/2MS medium contained 2.0 mg/L 6-BA and 0.5 mg/L NAA, and the best rooting medium was 1/2MS.
- Open Access
- 25 January 2018
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 16 (1) , 1-11
Establishment and genomic characterizations of patient-derived esophageal squamous cell carcinoma xenograft models using biopsies for treatment optimization
Squamous cell carcinoma is the dominant type of esophageal cancer in China with many patients initially diagnosed at advanced stage. Patient-derived xenografts (PDX) models have been developed to be an important platform for preclinical research. This study aims to establish and characterize PDX models using biopsy tissue from advanced esophageal cancer patients to lay the foundation of preclinical application. Fresh endoscopic biopsy tissues were harvested from patients with advanced esophageal cancer and implanted subcutaneously into NOD/SCID mice. Then, the PDXs were serially passaged for up to four generations. Transplantation was analyzed and genomic characteristics of xenografts were profiled using next-generation sequencing. Twenty-five PDX models were established (13.3%, 25/188). The latency period was 75.12 ± 19.87 days (50–120 days) for the first passage and it decreased with increasing passaging. Other than tumor stages, no differences were found between transplantations of xenografts and patient characteristics, irrespective of chemotherapy. Histopathological features and chemosensitivity of PDXs were in great accordance with primary patient tumors. Each PDX was assessed for molecular characteristics including copy number variations, somatic mutations, and signaling pathway abnormalities and these were similar to patient results. Our PDX models were established from real time biopsies and molecularly profiled. They might be promising for drug development and individualized therapy.
- 25 January 2018
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 16 (1) , 1-11
Open AccessEstablishment and genomic characterizations of patient-derived esophageal squamous cell carcinoma xenograft models using biopsies for treatment optimization
Squamous cell carcinoma is the dominant type of esophageal cancer in China with many patients initially diagnosed at advanced stage. Patient-derived xenografts (PDX) models have been developed to be an important platform for preclinical research. This study aims to establish and characterize PDX models using biopsy tissue from advanced esophageal cancer patients to lay the foundation of preclinical application. Fresh endoscopic biopsy tissues were harvested from patients with advanced esophageal cancer and implanted subcutaneously into NOD/SCID mice. Then, the PDXs were serially passaged for up to four generations. Transplantation was analyzed and genomic characteristics of xenografts were profiled using next-generation sequencing. Twenty-five PDX models were established (13.3%, 25/188). The latency period was 75.12 ± 19.87 days (50–120 days) for the first passage and it decreased with increasing passaging. Other than tumor stages, no differences were found between transplantations of xenografts and patient characteristics, irrespective of chemotherapy. Histopathological features and chemosensitivity of PDXs were in great accordance with primary patient tumors. Each PDX was assessed for molecular characteristics including copy number variations, somatic mutations, and signaling pathway abnormalities and these were similar to patient results. Our PDX models were established from real time biopsies and molecularly profiled. They might be promising for drug development and individualized therapy.
- Open Access
- 13 December 2017
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 15 (1) , 1-11
Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways
We investigated antitumor activity and underlying mechanisms of DNA topoisomerase I (TopI) inhibitor gimatecan and irinotecan in gastric cancer (GC) in vitro cell lines and in vivo patient-derived xenograft (PDX) models. GC cell lines SNU-1, HGC27, MGC803 and NCI-N87 were used to evaluate cell viability and apoptosis after gimatecan or irinotecan treatment, using a cell proliferation assay and flow cytometry, respectively. DNA TopI expression and critical molecules of PI3K/AKT, MAPK and apoptosis signaling pathways were analyzed with western blot. For in vivo studies, five PDXs models were treated with gimatecan or irinotecan to assess its antitumor activity. Immunohistochemistry staining of Ki-67 was performed after mice were sacrificed. Gimatecan inhibited the proliferation of GC cells in vitro in a dose- and time-dependent manner by inducing apoptosis, and gimatecan had greater inhibitory effects than irinotecan. In addition, both gimatecan and irinotecan demonstrated significant tumor growth inhibition in in vivo PDX models. Gimatecan treatment significantly inhibited the expression of DNA TopI, phosphorylated AKT (pAKT), phosphorylated MEK (pMEK) and phosphorylated ERK (pERK). Meanwhile, gimatecan could also activate the JNK2 and p38 MAPK pathway as indicated by upregulation of phosphorylated p38 MAPK (p-p38) and phosphorylated JNK2 (pJNK2). For the first time, we have shown that the antitumor activity of gimatecan in GC via suppressing AKT and ERK pathway and activating JNK2 and p38 MAPK pathway, which indicated that gimatecan might be an alternative to irinotecan in the treatment of GC.
- 13 December 2017
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 15 (1) , 1-11
Open AccessGimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways
We investigated antitumor activity and underlying mechanisms of DNA topoisomerase I (TopI) inhibitor gimatecan and irinotecan in gastric cancer (GC) in vitro cell lines and in vivo patient-derived xenograft (PDX) models. GC cell lines SNU-1, HGC27, MGC803 and NCI-N87 were used to evaluate cell viability and apoptosis after gimatecan or irinotecan treatment, using a cell proliferation assay and flow cytometry, respectively. DNA TopI expression and critical molecules of PI3K/AKT, MAPK and apoptosis signaling pathways were analyzed with western blot. For in vivo studies, five PDXs models were treated with gimatecan or irinotecan to assess its antitumor activity. Immunohistochemistry staining of Ki-67 was performed after mice were sacrificed. Gimatecan inhibited the proliferation of GC cells in vitro in a dose- and time-dependent manner by inducing apoptosis, and gimatecan had greater inhibitory effects than irinotecan. In addition, both gimatecan and irinotecan demonstrated significant tumor growth inhibition in in vivo PDX models. Gimatecan treatment significantly inhibited the expression of DNA TopI, phosphorylated AKT (pAKT), phosphorylated MEK (pMEK) and phosphorylated ERK (pERK). Meanwhile, gimatecan could also activate the JNK2 and p38 MAPK pathway as indicated by upregulation of phosphorylated p38 MAPK (p-p38) and phosphorylated JNK2 (pJNK2). For the first time, we have shown that the antitumor activity of gimatecan in GC via suppressing AKT and ERK pathway and activating JNK2 and p38 MAPK pathway, which indicated that gimatecan might be an alternative to irinotecan in the treatment of GC.
- Open Access
- 2 June 2017
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 15 (1) , 1-11
CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest
Cell cycle dysregulation is common in human malignancies, and CDK4/6 inhibitors targeting cell cycle have potential antitumor activity. SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway. However, the role of SHR6390 in esophageal squamous cell carcinoma (ESCC) remains unknown, which will be investigated in our study. Eca 109, Eca 9706, and KYSE-510 ESCC cell lines were chosen for further analysis. The effect of SHR6390 on cell viability, cell cycle and cell apoptosis, the status of kinases in Cyclin D1-CDK4/6-Rb pathway were determined by MTS assay, flow cytometry, and western blotting, respectively. Cell-derived and patient-derived xenografts were established to investigate the effects of drugs in vivo. SHR6390 could suppress cell proliferation in vitro cell lines and inhibit tumor growth in vivo PDX models with different drug susceptibility. The effective treatment of SHR6390 induced the inhibition of phosphorylated Rb and cell cycle arrest at G1 phase both in cell lines and in xenografts. SHR6390 combined with paclitaxel or cisplatin offered synergistic inhibitory effects in cell-derived xenografts especially in Eca 9706 xenografts which showed relative lower sensitivity of SHR6390 single. Moreover, low expression of CDK6 and/or high expression of Cyclin D1 might be associated with high sensitivity of SHR6390, which would be validated in the future. CDK4/6 inhibitor-SHR6390 exerted potential antitumor activity against ESCC cell lines and xenografts, and evaluation of CDK6 and Cyclin D1 expressions might be helpful to select patients beneficial from SHR6390, which provided evidences for future clinical trials.
- 2 June 2017
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 15 (1) , 1-11
Open AccessCDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest
Cell cycle dysregulation is common in human malignancies, and CDK4/6 inhibitors targeting cell cycle have potential antitumor activity. SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway. However, the role of SHR6390 in esophageal squamous cell carcinoma (ESCC) remains unknown, which will be investigated in our study. Eca 109, Eca 9706, and KYSE-510 ESCC cell lines were chosen for further analysis. The effect of SHR6390 on cell viability, cell cycle and cell apoptosis, the status of kinases in Cyclin D1-CDK4/6-Rb pathway were determined by MTS assay, flow cytometry, and western blotting, respectively. Cell-derived and patient-derived xenografts were established to investigate the effects of drugs in vivo. SHR6390 could suppress cell proliferation in vitro cell lines and inhibit tumor growth in vivo PDX models with different drug susceptibility. The effective treatment of SHR6390 induced the inhibition of phosphorylated Rb and cell cycle arrest at G1 phase both in cell lines and in xenografts. SHR6390 combined with paclitaxel or cisplatin offered synergistic inhibitory effects in cell-derived xenografts especially in Eca 9706 xenografts which showed relative lower sensitivity of SHR6390 single. Moreover, low expression of CDK6 and/or high expression of Cyclin D1 might be associated with high sensitivity of SHR6390, which would be validated in the future. CDK4/6 inhibitor-SHR6390 exerted potential antitumor activity against ESCC cell lines and xenografts, and evaluation of CDK6 and Cyclin D1 expressions might be helpful to select patients beneficial from SHR6390, which provided evidences for future clinical trials.
- Open Access
- 1 June 2017
- Published by Elsevier in Translational Oncology
- Vol. 10 (3) , 367-377
Characterization of Aurora A and Its Impact on the Effect of Cisplatin-Based Chemotherapy in Patients with Non–Small Cell Lung Cancer
- 1 June 2017
- Published by Elsevier in Translational Oncology
- Vol. 10 (3) , 367-377
Open AccessCharacterization of Aurora A and Its Impact on the Effect of Cisplatin-Based Chemotherapy in Patients with Non–Small Cell Lung Cancer